ImmuPharma Shares Jump as FDA Meeting Date Set for P140 Clinical Program
Provided by
Dow Jones
By Kyle Morris
Shares in ImmuPharma PLC jumped 16% on Wednesday after the company said that it has received Food and Drug Administration confirmation for a pre-investigational new drug meeting on May 16 to consider a Phase 2/3 adaptive trial study protocol for its late-stage P140 clinical program in patients with chronic idiopathic demyelinating polyneuropathy.
The company said that a new investigational new drug submission is required as this will be the first time that P140 is to be studied in humans for the indication of CIDP.
Shares at 0716 GMT were up 0.35 pence at 2.50 pence.
Write to Kyle Morris at kyle.morris@dowjones.com
(END) Dow Jones Newswires
April 12, 2023 03:47 ET (07:47 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
After Earnings, Is Coinbase Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
Is ServiceNow Stock a Buy After Earnings and Its Investor Day?
-
3 Stocks to Buy and 3 Stocks to Sell After Earnings
-
Today’s Market Volatility Could Provide Tomorrow’s Opportunities
-
40 of the Best Investment Picks
-
Tech Stock Dividends Are Changing the Face of Dividend Growth Investing
-
Roblox Earnings: Weakening Engagement Has Weighed On Growth
-
The Best Gaming Stocks to Buy
-
Energy Transfer Earnings: M&A Drives Guidance Increase In Solid Quarter
-
The Best Healthcare Stocks to Buy
-
Going Into Earnings, Is Home Depot Stock a Buy, a Sell, or Fairly Valued?